Why the study?
RdRp inhibitors are an emerging strategy against viral infections, highlighted by the 2018 FDA approval of baloxavir marboxil, despite the complexity of identifying new compounds.
RdRp inhibitors represent an emerging and promising therapeutic strategy against viral infections like influenza.
No takes yet. Share an insight, caveat, or question.
Supports advancing RdRp inhibitors into trials for influenza; leaves open clinical adoption pending randomized validation.
Giacchello et al. (2020) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: